Help me understand, please. Earlier you said "I find their endorsement of Brilacidin as 'a most potent drug against SARS-CoV-2 than the known antiviral drugs' compelling".
Here you are saying: "Microbial Pathogenesis is hardly a 'prestigious' journal. In fact, it's an open-access journal. For those who don't know what an open-access journal is, it's where the authors pay to publish."
(This was interesting: "Cited by 1 | Viewed by 6336")
ps. Dug around on the mdpi website: "open access publication is supported by the authors' institutes or research funding agencies by payment of a comparatively low Article Processing Charge (APC) for accepted articles." The APC for Viruses is 2200 (Swiss Francs, CHF). (converts to ~$2400US today) https://www.mdpi.com/about/apc